RVTY241220C120000
- 1.30
- +0.35+36.84%
Revvity Newsroom
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)
Thursday Indexes Pull back From Records While Bitcoin Sets New Ones | Wall Street Today
100k Bitcoin! Market Pulls Back After Records | Live Stock
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
December Starts With a Mixed Market | Live Stock
What You Can Learn From Revvity, Inc.'s (NYSE:RVTY) P/E
Gene Editing Market Forecast Report 2024, With Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
Stifel Nicolaus Remains a Hold on Revvity (RVTY)
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
What Are Wall Street Analysts' Target Price for Revvity Stock?
S&P 500, Dow Hit Records Right After Open | Live Stock
Revvity Is Maintained at Overweight by Barclays
Revvity Analyst Ratings
Barclays Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $135